Q-omics provides the consensus-scored NCEH1 profile across patient tissues and cancer cell-line models. NCEH1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NCEH1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, NCEH1 protein abundance shows 20,981 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where NCEH1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NCEH1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NCEH1 survival associations across molecular data types. NCEH1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NCEH1 RNA expression–survival associations across cancer types. High NCEH1 expression shows unfavorable associations in ACC, PAAD, LGG, HNSC and GBM, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NCEH1 RNA expression.
This table summarizes NCEH1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NCEH1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NCEH1 shows lower tumor expression in LUSC and higher tumor expression in HNSC, KIRC, BLCA, STAD and BRCA. The HNSC box plot shows higher NCEH1 RNA expression in tumor versus normal tissue (log2 FC = +1.226, t-test p < 0.001).
This table shows molecular features associated with NCEH1 in patient tissues and cancer cell lines. In patient samples, NCEH1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NCEH1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BONE.
